FDA Reduces Clinical Hold on Tekmira’s Ebola Treatment

Drug Industry Daily
A A
Canadian biotech company Tekmira will restart a Phase I trial of its TKM-Ebola RNA interference therapy in the coming weeks, following the FDA’s downgrading of a partial clinical hold that allows the company to administer repeat doses not greater than 0.24 mg/kg/day.

To View This Article:

Login

Subscribe To Drug Industry Daily